arrow
E

Emmanuelle Leteurtre

institut pasteur lille
H指数:52
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Diagnostic pitfalls and unmet needs in neuroendocrine neoplasms: The added value of collegial expert pathology review through the national TENpath network

神经内分泌肿瘤的诊断陷阱和未满足的需求:通过国家TENpath网络进行同行专家病理复查的附加价值

2026-09-010
PRE
Derepression of the epithelial transcription factor GRHL2 promotes direct hepatocyte-to-cholangiocyte transdifferentiation

上皮转录因子GRHL2的去抑制促进了直接的肝细胞到胆管细胞的转分化

2025-12-120
PRE
Resolution of Metabolic Dysfunction-associated Steatohepatitis With No Worsening of Fibrosis After Bariatric Surgery Improves 15-year Survival: A Prospective Cohort Study

代谢功能障碍相关脂肪性肝炎的代谢紊乱改善且纤维化无加重后,减重手术可提高15年生存率:一项前瞻性队列研究

2024-12-190
PRE
Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease

数据驱动的聚类分析确定不同类型的代谢功能障碍相关的脂肪性肝病

2024-12-090
OAAI
Time-of-day-dependent variation of the human liver transcriptome and metabolome is disrupted in MASLD
2024-01-012
OAAI
Combining diabetes, sex, and menopause as meaningful clinical features associated with NASH and liver fibrosis in individuals with class II and III obesity: A retrospective cohort study
OBESITY
IF4.7
2023-11-216
OAAI
CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas

晚期甲状腺癌中CDK4磷酸化状态和合理使用CDK4/6和BRAF/MEK联合抑制

2023-10-263
OAAI
Factors Associated with Survival in Anaplastic Thyroid Carcinoma: A Multicenter Study from the ENDOCAN-TUTHYREF Network
THYROID
IF6.7
2023-10-018
PRE
Second-line treatment and prognostic factors in neuroendocrine carcinoma: the RBNEC study
2022-10-019
PRE
Functional genomics uncovers the transcription factor BNC2 as required for myofibroblastic activation in fibrosis

功能基因组学揭示了纤维化中肌成纤维细胞激活所需的转录因子BNC2

2022-09-1016
OAAI
Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d'Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network
2021-07-0114
OAAI